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Abstract 
 
Background: Geraniol (G) is a natural isoprenoid present in the essential oils of 
several aromatic plants, with various biochemical and pharmacologic properties. 
Nevertheless, the mechanisms of action of geraniol on cellular metabolism are 
largely unknown.  
Hypothesis/Purpose: We propose that geraniol could be a potential agent for the 
treatment of hyperlipidemia that could contribute to the prevention of cardiovascular 
disease. The aim of the present study was to advance our understanding of its 
mechanism of action on cholesterol and TG metabolism. 
Study Design/Methods 
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NIH mice received supplemented diets containing 25, 50, and 75 mmol G/kg chow. 
After a 3-week treatment, serum total-cholesterol and triglyceride levels were 
measured by commercial kits and lipid biosynthesis determined by the [14C] acetate 
incorporated into fatty acids plus nonsaponifiable and total hepatic lipids of the 
mice. The activity of the mRNA encoding HMGCR—the rate-limiting step in 
cholesterol biosynthesis—along with the enzyme levels and catalysis were assessed 
by real-time RT-PCR, Western blotting, and HMG-CoA-conversion assays, 
respectively. In-silico analysis of several genes involved in lipid metabolism and 
regulated by geraniol in cultured cells was also performed. Finally, the mRNA levels 
encoded by the genes for the low-density-lipoprotein receptor (LDLR), the sterol-
regulatory-element-binding transcription factor (SREBF2), the very-low-density-
lipoprotein receptor (VLDLR), and the acetyl-CoA carboxylase (ACACA) were 
determined by real-time RT-PCR. 
Results: Plasma total-cholesterol and triglyceride levels plus hepatic fatty-acid, total-
lipid, and nonsaponifiable-lipid biosynthesis were significantly reduced by geraniol 
feeding. Even though an up-regulation of the mRNA encoding HMGCR occurred in 
the geraniol-treated mouse livers, the protein levels and specific activity of the 
enzyme were both inhibited. Geraniol also enhanced the mRNAs encoding the LDL 
and VLDL receptors and reduced ACACA mRNA, without altering the transcription 
of the mRNA encoding the SREBF2. 
Conclusions: The following mechanisms may have mediated the decrease in plasma 
lipids levels in mice: a down-regulation of hepatocyte-cholesterol synthesis occurred 
as a result of decreased HMGCR protein levels and catalytic activity; the levels of 
LDLR mRNA became elevated, thus suggesting an increase in the uptake of serum 
LDL, especially by the liver; and TG synthesis became reduced very likely because 
of a decrease in fatty-acid synthesis. 
 
Keywords: Geraniol, Hypolipemia, Lipogenesis, HMGCR, ACACA 
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Abbreviation: 
ACACA: acetyl-CoA carboxylase  
G: Geraniol 
HMG-CoA: 3-hydroxy-3-methylglutarylcoenzyme-A 
HMGCR: 3-hydroxy-3-methylglutarylcoenzyme-A reductase  
LDL: low-density-lipoprotein  
LDLR: low-density-lipoprotein receptor  
MP: mevalonate pathway  
RT-PCR: reverse-transcriptase–polymerase-chain reaction  
SREBF2: sterol-regulatory-element–binding transcription factor  
TG: triglyceride  
VLDL: very-low-density-lipoprotein  
VLDLR: very-low-density-lipoprotein receptor  
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1 . In tro d u ctio n  
 Geraniol (G) is an acyclic monoterpene derived from the mevalonate pathway 
(MP) in plants, but not produced in mammals. This natural isoprenoid—present in 
the essential oils of diverse aromatic plants—is produced by the flowers but is 
present in the vegetative tissues from species of the Rosaceae, Poaceae, Lamiaceae, 
Geraniaceae, Rutaceae families. Because of its organoleptic features, geraniol is one 
of the most frequently used compound in the fragrances and flavoring industries 
(Chen and Viljoen, 2010; Lapczynski et al., 2008). This terpenoid has previously 
shown antiproliferative activity against human tumor cells both in culture and in 
vivo (Ahmad et al., 2011; Burke et al., 1997; Cardozo et al., 2011; Carnesecchi et 
al., 2001; Galle et al., 2014; Jin et al., 2013; Ong et al., 2006). G appears to decrease 
tumor growth by cell-cycle arrest, apoptosis induction, and autophagy (Cardozo et 
al., 2011; Chaudhary, et al., 2013; Kim et al., 2012; Ong et al., 2006; Wiseman et 
al., 2007). Nevertheless, the mechanisms of action of geraniol on cellular 
metabolism are largely unknown. The MP has been reported as a metabolic 
sequence modulated by isoprenoids (Mo and Elson, 2004; Ong et al., 2006). In 
addition to cholesterol, the pathway generates several other molecules relevant to 
general cellular metabolism, such as farnesyl pyrophosphate and geranyl-geranyl 
pyrophosphate, essential in the prenylation of a variety of proteins including the 
small GTPase Ras, which plays a critical role in cell-cycle progression. The rate-
limiting enzyme of the MP is 3-hydroxy-3-methylglutarylcoenzyme-A reductase 
(HMGCR), a protein that is transcriptionally regulated by the sterol-regulatory-
element–binding transcription factor (SREBF2). 
 Our recently published work (Galle et al., 2014) performed in a mouse model 
in which geraniol exerted antitumor activity as well as caused the inhibition of the 
MP, also demonstrated a reduction of plasma cholesterol and triglyceride (TG) 
levels in tumor-bearing host mice. Whether the hypolipidemic effect was caused by 
an increase in the tumor's lipid requirements for growth or by the presence of 
geraniol itself, however, remained unclear. The aim of the present study was to 
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advance our understanding of the mechanism of action of this monoterpene on 
cholesterol and TG metabolism in non–tumor-bearing mice. For this purpose we 
evaluated the plasma-lipid content, the lipid-biosynthetic levels, and the genetic 
expression of certain key proteins involved in the regulation of those lipid levels that 
had been previously found to be modified with geraniol in cultured cells and in vivo 
(Crespo et al., 2013; Galle et al., 2014; Jayachandran et al., 2014): namely, 
HMGCR, -acetyl-CoA carboxylase (ACACA, catalyzing the rate-limiting step in 
fatty-acid biosynthesis), SREBF2, the low-density-lipoprotein (LDL) receptor, 
(mediating LDL-cholesterol internalization into the cell), and the very-low-density-
lipoprotein (VLDL) receptor—it apparently playing an essential role in the uptake 
and degradation of fatty acids and TG-rich particles (Crawford et al., 2008). 
 
2 . Mate rials  an d  m e th o d s   
2.1 Reagents 
 Geraniol (98%) was obtained from Sigma (St. Louis, MO, USA), inorganic 
reagents and solvents of analytical grade from Merck (Darmstadt, Germany), 
analyticals from Carlo Erba (Milan, Italy) and Sigma, and [
14
C] acetate (54.7 
Ci/mol) from Perkin Elmer Life Science, Inc. (Boston, MA, USA). Merck, Sharp 
and Dohme (Argentina) kindly provided simvastatin. 
 
2.2 Animals and diets 
 Female NIH nu/nu mice were obtained from the Bioterio of Centro Atómico 
Ezeiza (CNEA) and housed in a temperature-controlled room on a 12/12-h cycle of 
light and darkness. The animals were maintained ad libitum on a gamma-irradiated-
chow diet and autoclaved water. Two-month-old mice with 20–25g weight were 
randomly separated into one control group and three experimental groups, with the 
latter receiving supplemented diets containing 25, 50, and 75 mmol G/kg chow as 
described in previous reports (Yu et al., 1995; Galle et al., 2014). A positive control 
for hypolipidemic effects was included; this group was treated with 50 mg/kg body 
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weight of simvastatin per day in the drinking water. After a 3-week treatment, all 
mice were injected with radioactive acetate (25 µCi/animal) and three h later killed 
by cervical dislocation in the middle of the light period. All experiments on animals 
were performed in conformity with Guidelines of Handling and Training of 
Laboratory Animal (Wolfensohn and Lloyd, 2013). The animal-use protocols 
employed were approved by the Institutional Animal Care and Use Committee 
(IACUC), Facultad de Ciencias Médicas, Universidad Nacional de La Plata. 
Protocol number 04-001-13. 
 
2.3 Blood measurements 
 Samples—removed from serum prepared from mouse blood obtained by 
cardiac puncture at sacrifice—were placed at 37 °C for 30 min, centrifuged for 10 
min at 3000 x g, and then stored at –20 °C until analysis. Cholesterol and TG 
concentrations were determined by commercial kits (Wiener, Argentina) adapted to 
use with mice. The samples were incubated at 37 °C for 5 min and the A
505 
measured within 30 min in a Beckman Coulter DTX 880 Microplate Reader. A 
standard curve of A505vs.cholesterol or TG concentration was plotted and the total 
concentrations in the sample calculated from the standard curve. 
 
2.4 Tissue collection and histological analysis 
 Whole livers were removed from the mice and the total-liver weights 
measured. Fresh-liver blocks were cut and immediately fixed in 10% (v/v) buffered 
formaldehyde, then dehydrated in graded alcohols and embedded in paraffin. 
Sections of 6-µm thickness were rehydrated and stained with hematoxylin-eosin and 
the stained sections observed under light microscopy. 
 
2.5 Liver- lipid extraction and analysis 
 Liver lipids were extracted with chloroform:methanol (2:1, v:v) (Folch, Lees, 
& Sloane Stanley, 1957). In one aliquot from the organic phase, the TGs and the free 
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and esterified cholesterol were separated by thin-layer chromatography on silica gel 
geraniol developed in hexane/diethylether/acetic acid 80/20/1 (v/v/v), revealed 
through the use of a spray reagent containing an acidic ferric-chloride solution 
(Dudley & Anderson, 1975; Ren and Gould, 1994; Wilson and Sargent, 1992), and 
finally quantified by means of a curve constructed with pure standards (free 
cholesterol, esterified cholesterol, and trimiristine) that had been run on the same 
plate. The spots' images were analyzed by the Image J program. Another aliquot was 
used for measuring the radioactivity incorporated into total liver lipids and into the 
nonsaponifiable fraction plus the fatty acids resulting from a previous saponification 
reaction with 10% (w/v) KOH in methanol at 85 °C for 45 min. The nonsaponifiable 
lipids were extracted with petroleum ether, while after acidification the fatty acids 
were further extracted from the aqueous phase with petroleum ether. 
 The radioactivity was measured in a Wallac 1214 Rackbeta liquid-
scintillation counter (Pharmacia, Turku, Finland). 
 
2.6 RNA isolation and analysis by the real-time reverse-transcriptase–polymerase-
chain reaction 
 Total RNA was extracted from mouse liver through the use of the TRI 
Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) followed by a 
DNAase-I treatment (Fermentas Life Sciences, city, country). The cDNA was then 
synthesized by means of the kit qScriptTM cDNA SuperMix (Quanta Bioscences, 
Inc., city, country). The analysis by the real-time reverse-transcriptase–polymerase-
chain reaction (real-time RT-PCR) was run through the use of the PerfeCtaTM 
SyberGreenFastMixTM and the StratageneMX30005P real-time–RT-PCR System. 
The PCR conditions were 94 °C for 4 min, followed first by 40 cycles with each one 
under the following conditions: 94 °C for 40 s, 57 °C for 40 s, and 72 °C for 40 s; 
and then by a final cycle at 95 °C for 1 min, 55 °C for 30 s, and 95 °C for 30 s. The 
relative amount of mRNA was calculated by means of the comparative-threshold-
cycle method and the qBase v1.3.5 program with ß-actin as the reference 
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housekeeping gene. The oligonucleotide primers used are summarized in Table 1. 
The amplified fragments were detected by electrophoresis on a 1.8% (w/v) agarose 
gels after Sybr-Green-I staining. 
 
2.7 HMGCR in the microsomal fraction 
 Mouse-liver tissue was placed (1:10, w/v) in cold homogenization buffer 
containing 0.3 M sucrose, 50 mM NaCl, 10 mM sodium ethylenediaminetetracetic 
acid, 10 mM dithiothreitol, and 50 mM Tris-HCl (pH 7.4). The minced tissue was 
homogenized at 4 °C in a TRI–R 5630 homogenizer [commercial source]. Samples 
were centrifuged at 12,000 x g and 4 °C for 15 min and the resulting supernatant 
fraction at 105,000 x g and 4 °C for 60 min. The final microsomal pellets were 
immediately frozen at –70 °C for storage until use. Before the assay for HMGCR 
activity, each pellet was resuspended in buffer containing 5 mM dithiothreitol and 
20 mM imidazole chloride (pH 7.4). The protein content of each sample was 
determined by the method of Bradford (1976) with bovine-serum albumin as 
standard. 
 The spectrophotometric assay of the solubilized HMGCR containing 0.2 mM 
NADPH and 0.1 mM RS-HMG-CoA in phosphate buffer (0.2 M KCl, 0.16 M 
potassium phosphate, 0.004 M ethylenediaminetetracetic acid, and 0.01 M 
dithiothreitol, pH 6.8) was carried out at 37 °C through the use of a Beckman 
Coulter DTX 880 Microplate Reader. One unit of HMGCR activity was defined as 1 
pmol of NADPH consumed per min per mg microsomal protein. 
 For Western blotting, microsomal proteins were boiled in the sample buffer 
(Tris-HCl 0.06M pH 6.8, Glycerol 1%, Bromophenol blue 0.02%, SDS 2%, ß-
mercaptoethanol5%) for 5 min. The samples were separated on 12.5% (w/v) 
sodium-dodecylsulfate–polyacrylamide gels and adsorbed to 
polyvinylidenedifluoride membranes (Amersham, GE Healthcare,[commercial 
source]) by a semidry transfer at 10 V for 1 h in 20% (v/v) methanol in 39 mM 
glycine, 48 mM Tris pH 8.3. The nonspecific protein-binding sites were blocked by 
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incubation in PBS (pH 7.4) containing 0.05% (v/v) Tween 20 plus 5% (v/v) 
skimmed milk. The membrane was incubated with anti-HMGCR (Santa Cruz, CA, 
USA) diluted 1/200 in antibody-dilution buffer (2% [v/v] skimmed milk in PBS plus 
0.1% [v/v] Tween 20) for 1 h followed by three 5-min washes in the same buffer. 
Horseradish-peroxidase–conjugated antibodies (Santa Cruz, CA, USA) were added 
to the membrane for 1 h. As an internal control, polyvinylidenedifluoride 
membranes were stained with Coomassie blue G-250. 
 Immunoreactive bands were detected by enhanced-chemiluminescence 
Western-blot–detection reagents (Amersham Pharmacia Biotech, city, country) and 
processed manually through the use of common X-ray-film developers and fixers. 
Protein immunoblots were scanned and the density of each band quantified with the 
ImageJ software (Image processing and analysis in Java). 
 
2.8 In-silico analysis 
 The effect of geraniol on the gene-expression profiles of loci associated with 
lipid metabolism was assessed in silico. We employed the dataset GSE45567 
obtained from GEO (http://www.ncbi.nlm.nih.gov/geo/), in which several 
compounds, including geraniol, were evaluated in triplicate on the PC-3 permanent 
cell-culture line (Lee et al., 2013). These cells—originally derived from a human-
prostate cancer and containing prostasome membranes enriched in lipid rafts of 
cholesterol and sphingomyelin (Llorente et al., 2007)—synthesize and accumulate 
more cholesterol than normal prostate epithelial cells (Li et al., 2006). The relevant 
data were downloaded as .CEL files and normalized with the frozen robust 
multiarray-analysis (fRMA) algorithm in the open-source statistical software R. 
From the normalized matrix obtained, the vehicle- and geraniol-treated samples 
were extracted and compared statistically. A total of 64 genes—grouped into 7 
functional categories—were analyzed (Supplementary material). 
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 We applied the unsupervised-hierarchical-clustering method by means of the 
MeV software (www.tm4.org/mev.html) with the Pearson correlation coefficient as 
a measurement of distance and complete linkage.  
 
2.9 Statistical analysis 
 The results are expressed as the means ± S.E.M., and all analyses were 
conducted with GraphPadInStat 3.0. Statistical differences between the control and 
the geraniol-treated animals were evaluated by the ANOVA test followed by the 
Tukey HSD post-hoc comparisons. Differences were considered significant at a p < 
0.05. For the in-silico analysis, the differences in the gene-expression profiles 
between the samples exposed to the vehicle and those treated with geraniol were 
evaluated by the TTest (Dudoit et al., 2002; Pan, 2002) at a significance threshold of 
0.05% (Supplementary material). 
 
3 . Re su lts  
3.1 Serum-cholesterol and -TG levels after geraniol treatment   
 Mice treated with 25, 50, and 75 mmol G/kg chow manifested a decrease in 
serum cholesterol and TGs (Fig. 1), and this effect became significant (p < 0.05) in 
the mice treated with 50 and 75 mmol G/kg chow. Moreover, in mice fed with the 
highest dose of geraniol, the reduction in serum-TG content compared to the 
controls was much more pronounced than that of the cholesterol (by 58.2% and 
18.7%, respectively). The effect of simvastatin (50 mg/kg), as a standard 
hypolipidemic drug, was similar to that obtained with the lowest dose of geraniol 
(Fig. 1). In order to compare geraniol with simvastatin, geraniol impregnated into 
the chow was quantified by capillary gas chromatography  (data not shown), which 
determination suggested that 25, 50, and 75 mmol geraniol added per kg of the 
chow, would result  in 100, 200, and 300 mg G/kg body weight of each animal per 
day, respectively. 
 The decrease in these blood lipids seemed not to produce any adverse side 
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effects in the mice since after the 3-week experimental period the final body and 
liver weights, as well as the levels of food intake, in the treated mice were not 
significantly different from the corresponding values in the control mice (Table 2). 
This outcome contrasts with what is commonly observed in animals subjected to 
toxic compounds (Wang et al., 2007). Moreover, the general histologic organization 
of the livers of the G-fed mice was similar to that of the control mice: none of the 
animals manifested hepatic steatosis, an accumulation of pigments, a congestion of 
the hepatic vessels, or the presence of macrophages and lymphocyte infiltrates (Fig. 
2 A-D). 
 
3.2 Liver-lipid profile and lipid synthesis of mice treated with geraniol 
 In contrast to the results with serum, when the content of TGs and of free and 
esterified cholesterol were analyzed in the livers of geraniol-treated mice, no 
significant differences were found in any of those lipid classes with respect to the 
control values (Fig. 3A, B). 
 When the incorporation of [
14
C]acetate into total lipids, fatty acids, and 
nonsaponifiable lipids was investigated, low doses of geraniol (25 mmol/kg chow) 
did not significantly decrease the radiolabelling in the total lipids, but at 50 or 75 
mmol G/kg chow, a diminution in incorporation became progressively significant. 
Fatty-acid synthesis was significantly inhibited only at the highest dose of geraniol, 
whereas nonsaponifiable-lipid synthesis was substantially reduced at all three doses 
of the isoprenoid (Fig. 4). 
 
3.3 In silico analysis of the effect of geraniol on lipid metabolism and the expression 
of related genes in PC-3 cells 
 Hierarchical clustering revealed two stable groups, the vehicle-exposed (a 
working solution of 0.01% [v/v] ethanol) and the geraniol-treated cells. Similarly, at 
the genetic level two stable clusters were identified from the first node of the 
dendogram. We designated these clusters as being up-regulated or down-regulated 
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upon treatment with geraniol. That the genes related to lipogenesis all segregated 
into the down-regulated cluster, whereas those involved in lipoprotein metabolism 
all seemed to be activated by geraniol treatment was most interesting. The 
distribution of genes from the other functional categories varied between the two 
clusters: The genes encoding bile-acid metabolism and cholesterol excretion showed 
a tendency to be activated, with 6 genes in the up-regulated versus 3 in the down-
regulated cluster (at 66% overall); the genes related to cholesterol transport 
exhibited the reverse pattern, with 3 out of 4 in the down-regulated cluster (at 75% 
overall); the genes responsible for lipolysis and ß-oxidation were principally up-
regulated, with 5 out of 7 in that cluster (at 71% overall); and finally the genes 
governing the MP proved to be essentially divided, with 13 out of 20 in the down-
regulated cluster (65% overall; Fig. 5A). 
 TTest analysis for these genes between the vehicle-exposed and the geraniol-
treated cells—at a significance level of 0.05—indicated that ACSL1, ABCA1, 
DHCR24, ACAT2, ACACA, ABCG1, ACAD9, ACACB, IDI1, PPARG, SCD, 
SCARB1, HMGCS1, EBP, DHCR7, FASN, HMGCR, and GPAM were down-
regulated upon G treatment; whereas NR1H2, PPARA, INSIG2, CPTP1, APOE, 
VLDLR, ABCC2, and SREBF2 were activated after exposure to geraniol (Fig. 5, 
Panel B). Furthermore, the reverse cholesterol transport, lipogenesis, and MP 
biofunctions were down-regulated. On the basis of these results and the previous 
data from our own laboratory, we decided to validate five of these genes (HMGCR, 
ACACA, LDLR, VLDLR, and SREBF2) in the livers of geraniol-treated mice, as 
this organ plays a major role in cholesterol and lipid metabolism (van der Wulp et 
al., 2013). 
 
3.4 Effect of geraniol on the HMGCR of mouse liver 
 The analysis of HMGCR expression by real-time RT-PCR revealed a dose-
dependent increase in the mount of the mRNA encoding the enzyme. The highest 
dose of geraniol (75 mmol G/kg chow) produced a statistically significant rise in the 
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mRNA levels in the livers of the mice compared to the control values (Fig. 6, Panel 
A). Nevertheless, the levels and specific activities of the protein in the microsomes 
decreased reciprocally with increases in the doses of G (Fig. 6, panels B and C), 
resulting in a statistically significant effect on each of the two parameters at 
respective doses of 75 and 50 plus 75 mmol G/kg chow. 
 
3.5 Effect of geraniol on the LDL-receptor–, ACACA-, VLDL-receptor–, and 
SREBF2-mRNA transcription 
 In order to evaluate cholesterol uptake by the liver, we measured the 
transcriptional expression of the LDL receptor. As determined by real-time RT-
PCR, the LDL receptor mRNA was significantly increased in mice fed with 50 and 
75 mmol G/kg chow (Fig. 7A). The SREBF2-mRNA levels, however, did not vary 
significantly under either feeding condition (Fig. 7, Panel B). To ascertain the 
possible reason for the decrease in serum TG, we evaluated the mRNA levels of 
ACACA, the rate limiting enzyme in the fatty-acid synthesis. We observed that 
geraniol tended to inhibit ACACA transcription in animals treated with the middle 
dose, with this inhibition becoming statistically significant at 75 mmol G/kg chow 
(Fig. 8A). Moreover, by measuring the VLDL-receptor mRNA we also were able to 
evaluate the TG removed from VLDL by liver cells. These results indicated that the 
VLDL-receptor expression was up-regulated by geraniol (Fig. 8B). This increased 
transcription was statistically significant in mice fed with 50 mmol G/kg chow. 
Finally, most of these determinations of gene expression by real-time RT-PCR were 
consistent with the analyses in silico illustrated in Fig. 5. 
 
4 . Discu ssion  
 In the present work we have demonstrated that geraniol, a natural 
monoterpene present in the essential oils of several plants, significantly diminished 
the triglyceride and cholesterol levels in mouse blood, without exerting any effect on 
the animals' gain in body weight, food intake (Table 2), or liver histology (Fig. 2). 
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Furthermore, mice fed with 50 and 75 mmol G/kg of the diet exhibited a reduction 
in the synthesis of total liver lipids, especially with respect to the nonsaponifiable 
fraction (Fig. 4), where cholesterol biosynthesis was presumably the main process 
inhibited by geraniol, as we had demonstrated in several previous studies on 
cultured cells (Crespo et al., 2013; Polo et al., 2011; Polo et al., 2006). These results 
encouraged us to consider geraniol as a phytochemical with potential as an agent for 
combatting hypercholesterolemia. Since 50% or more of the total cholesterol in 
humans derives from de-novo synthesis, one of the most effective means to reduce 
the sterol's levels is undoubtedly an inhibition of its endogenous synthesis at the 
hepatic level (Vallianou et al., 2011). We suggest that HMGCR inhibition would be 
one of the multiple effects that isoprenoid compounds seem to be exerting on the 
MP, though that possibility had not yet been specifically elucidated previously. Only 
few citations in the literature (Duncan et al., 2004; Peffley and Gayen, 2003)—in 
addition to previous studies from our laboratory (Crespo et al., 2013) and the data 
obtained from the in-silico analysis presented here—have documented both a 
transcriptional and a posttranscriptional inhibition of the enzyme in cultured tumor 
cells. Our in-vivo results are in accord with the aforementioned reports on cultured 
cells since the animals treated with geraniol evidenced a decrease in both the levels 
and the activity of hepatic HMGCR even though the enzyme-specific mRNA levels 
increased in a dose-dependent manner (Fig. 6). 
 Regarding the regulation of HMGCR messenger levels, despite the indication 
by in-silico analysis that SREBF2 mRNA—which transcript modulates the 
expression of the HMGCR structural gene—was overexpressed in cultured geraniol-
treated cells, our work demonstrated that those regulatory-mRNA levels did not vary 
in the livers of mice treated with geraniol (Fig. 7); possibly because, in addition to 
affecting the SREBF2 gene's expression at the transcriptional level, the monoterpene 
could be regulating, directly or indirectly, the maturity mechanism of this 
transcription factor—involving a cleavage in the endoplasmatic reticulum and thus a 
prevention of nuclear migration—in agreement with the reports of Espenshade & 
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Hughes (2007) and Sato (2009).  
 In order to gain a more complete understanding of the role of SREBF2 
transcription in the modulation of cholesterol levels under these experimental 
conditions, we also evaluated the effect of geraniol on LDL-receptor mRNA—its 
gene constituting another target of the mature SREBF2 mRNA (Sato, 2009)—since 
one of the mechanisms that participates in cellular-cholesterol homeostasis is the 
uptake of cholesterol from the serum mainly through the internalization of LDL-
cholesterol via the LDL receptor (Chang et al., 2006) within the LDL pathway 
(Goldstein and Brown, 1990). The increase in LDL-receptor mRNA in mice treated 
with all three geraniol doses was only statistically significant from the second dose 
assayed, which response correlated with the diminution observed in serum-
cholesterol levels (Fig. 7, Panel A and Fig. 1, respectively). These results, together 
with the observation that the cholesterol levels in liver were not modified by the 
treatments with geraniol (Fig. 3), suggest the occurrence of an overexpression of the 
LDL-receptor gene to produce an increased uptake of exogenous cholesterol as a 
compensatory mechanism to offset the decrease in endogenous cholesterogenesis. 
 Geraniol also produced a decline in serum TG (Fig. 1). Moreover, the 
decreases in the incorporation of [
14
C]acetate into fatty acids in the livers of the 
treated mice (Fig. 4) along with the drop in the ACACA-mRNA levels (Fig. 8) 
support the hypothesis that the lowering of the serum TG concentration effected by 
geraniol could have been mediated by that concomitant inhibition of the synthesis of 
fatty acids. Nevertheless, serum TG significantly decreased with doses of geraniol 
that did not yet produce a statistically significant inhibition in fatty-acid synthesis 
(cf. Figs. 1 and 4). Consequently, we consider that other regulatory mechanisms 
involved in the metabolism of fatty acids could be operating to produce the lowering 
of serum TG. Since VLDL transports TG in the serum and the VLDL receptor has 
been proposed to bind VLDL as well as lipoprotein lipase and thus facilitate 
lipolysis (Crawford et al., 2008; Tacken et al., 2000)—or even to induce VLDL 
uptake (Guo-Min et al., 2012)—the overexpression of the VLDL-receptor gene 
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induced by G (Fig. 8) should be associated with an elevated removal of TG from the 
serum. Furthermore, similar hypolipidemic effects and molecular mechanisms have 
been shown in mice treated with the essential oils from Melissa officinalis (Jun et 
al., 2014). Accordingly, on the basis of the in-silico analyses presented here, we 
hypothesized that geraniol induced a fundamental change in the expression of 
several key genes involved in lipid metabolism resulting in a significant decrease in 
lipogenic-gene expression, particularly those related to the synthesis of cholesterol, 
fatty acids, and the saponifiable lipids; all of those gene products being targets for 
SREBF2 and SREBF1c. Furthermore, SREBF1c expression was down-regulated 
and nuclear-receptor-gene expression also modified by geraniol (cf. Fig. 5): there the 
peroxisome proliferator-activated receptor-(PPARA) and the farnesoid X receptor 
(FXR aka NR1H4) were up-regulated, whereas the liver X receptor (LXR aka 
NR1H3) was down-regulated. Another relevant action of geraniol concerns lipid 
trafficking in blood, as most genes involved in reverse cholesterol transport and 
lipoprotein metabolism have had their transcription modified under the influence of 
that monoterpene. Fig. 9 shows the model we propose for the overall effects of 
geraniol, as suggested from the results obtained in the present work, in our previous 
studies (Crespo et al., 2013; Galle et al., 2014), and from the literature (Goto et al., 
2011; Jun et al., 2014; Takahashi et al., 2002). 
 In this model, high levels of both the cholesterol and the TGs in serum along 
with the presence of oxidized LDL—it accelerating atherogenesis—increase the risk 
of coronary disease (Chung et al., 2008). Because of the action of geraniol in 
lowering the levels of both of these compounds selectively in the serum 
compartment, we propose that geraniol—a natural compound having such 
pronounced hypolipidemic effects—could well constitute an effective prophylactic 
or therapeutic agent for the prevention and/or treatment of cardiovascular disease. 
 
5 . Co n clu sio n s  
 In the present work we have demonstrated that mice administered geraniol 
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had significantly lower levels of serum cholesterol and TG. The following 
mechanisms may have mediated this effect: First, a down-regulation of hepatocyte-
cholesterol synthesis occurred as a result of decreased HMGCR protein levels and 
catalytic activity. Second, the levels of LDLR mRNA became elevated, thus 
suggesting an increase in the uptake of serum LDL, especially by the liver. Three, 
TG synthesis became reduced very likely because of a decrease in fatty-acid 
synthesis. 
 Dietary phytochemicals may alter gene expression in different ways. The 
results from these experiments provide information on the effects of geraniol on the 
metabolism of specific lipids that should contribute to a decrease in the risk of 
cardiovascular disease. To our knowledge, this investigation is one of the first 
studies demonstrating that geraniol could constitute a potential prophylactic and/or 
therapeutic agent by lowering both the cholesterol and the TG in serum so as to 
contribute to a primary as well as a secondary prevention of coronary disease. 
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Table  le ge n d s 
Table 1 Real-time–RT-PCR–primer sequences 
 
Gene Primer Sequence (5´-3´) 
HMGCR 
Forward TGTCCTTGATGGCAGCCTTG 
Reverse CGCGCTTCAGTTCAGTGTCAG 
LDLR 
Forward GCAGTAGCTCGCTCTCGTTG 
Reverse TGGCAATGGATCCCGGAAAG 
SREBF2 
Forward AAGGCTGGCCCATAGCTTC 
Reverse GCAGTAGCTCGCTCTCGTTG 
VLDLR 
Forward AGCGCTTCTGTAGGACACAC 
Reverse CTTCAGCGCTGGCTCTGTTA 
ACACA 
Forward GACAGAGGAAGATGGCGTCC 
Reverse AGATGTGCTGGGTCATGTGG 
ß-actin 
Forward TCAAGATCATTGCTCCTCCTGAG 
Reverse CTCCTGCTTGCTGATCCACA 
 
Table 2 Effect of geraniol in body and liver weight and in the food intake of mice 
during a 3-week experimental period. After that exposure to G (at 0, 25, 50, and 75 
mmol G/kg food) body weight (BW), liver weight (LW), food intake, and geraniol 
intake were measured in the treated and control mice. Values are the means ± SEM 
(n = 5). Values in a row with similar superscript letters do not differ significantly (p 
0.05). 
 
  Control           mmol G/Kg chow 
    25 50 75 
Initial BW (g) 20.5 ± 0.4a 20.6 ± 0.2a 21.0 ± 0.4a 20.8 ±0.4a 
Final BW(g) 25.0± 0.5a 24.0±0.5a 24.5 ±0.2a 24.1 ±0.4 a 
LW(g) 1.60±0.07a 1.56±0,06a 1.60±0,05a 1.52±0.06a 
LW / BW 0.064 ±0.002a 0.065±0.002
a 0.065±0.002a 0.063±0.002a 
Food intake (g/day) 4.10 ± 0.26a 3.96 ± 0.26a 4.02±0.25a 3.88±0.23a 
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Figu re  le ge n d s 
 
Fig. 1. Effect of geraniol on serum cholesterol and triglycerides. After three weeks 
of treatment with geraniol (0, 25, 50, and 75 mmol/kg chow) or simvastatin 
(50mg/kg), serum samples were collected and serum cholesterol and triglycerides 
measured as described in Materials and Methods. The values represent the means ± 
SEM, 5 ≤ n ≤ 8. (*) p < 0.05, (**) p < 0.01 vs. control group; (##) p < 0.01 vs. group 
treated with 25 mmol G/kg chow 
 
Fig. 2. Histological appearance of livers from mice treated with geraniol. NIH 
nu/nu mice received either standard chow alone (controls; panels A and C) or 
supplemented with geraniol (50 mmol/kg chow; panels B and C) for three weeks. 
Original magnification: 10X (Panels A and B) and 40X (panels C and D); Slices of 
6-µm thickness were stained with hematoxylin and eosin.  
 
Fig. 3. Effect of geraniol on hepatic-lipid content. Liver lipids were extracted and 
separated by thin-layer chromatography and the spots visualized with FeCl3.H2SO4 
(Panel A). The relative quantities of free cholesterol (FC), esterified cholesterol 
(EC), and triglycerides (TG) were quantified by measuring the intensity of each 
band (Panel B). The results are expressed as means ± SEM, n = 5. 
 
Fig. 4. Incorporation of [
14
C] acetate into the liver lipids of mice fed geraniol. The 
radioactivity incorporated into total liver lipids (TL), nonsaponifiable lipids (NL), 
and fatty acids (FA) was measured by liquid-scintillation counting. The data are the 
means ± SEM, n = 5. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001. 
 
Fig. 5. In-silico analysis, in triplicate, of the mRNA-expression profile of lipid-
associated genes in the PC-3 cell line. PC-3 cells were exposed to geraniol or only 
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to the vehicle (a working solution of 0.01% [v/v] ethanol) as a control. Panel A. 
Unsupervised hierarchical clustering clearly defined two groups of samples, which 
distinction indicated that geraniol exerted its effect on gene expression. Moreover, 
from the first node of the gene tree, two groups were identified: the upper cluster 
(designated down-regulated) with genes whose expression decreased upon treatment 
with geraniol and the lower cluster (designated up-regulated) with genes whose 
expression increased upon treatment with geraniol. The figure also indicates how the 
biologic processes associated with these genes were likewise distributed according 
to the hierarchical clustering. Panel B. To determine whether these differences were 
significant, a TTest analysis and subsequent hierarchical clustering of the significant 
genes was conducted. Out of 64 genes, 30 showed statistical differences (p < 0.05). 
We then decided to validate in our mouse model five of those genes (indicated by 
the red and green arrows), of which the figure shows box-whisker plots of their 
expression profile in the PC-3 cells.Genes are named with the official symbol 
according to HGNC (HUGO Gene Nomenclature Committee) 
 
Fig. 6. HMGCR in mice treated with geraniol. The mRNA levels of liver HMGCR 
were determined by real-time RT-PCR (Panel A), while the quantity of enzyme 
protein was measured by Western blotting (Panel B). Under this graph are also 
shown the Western-blot densities of immunoreactive HMGCR protein (above) and 
the polyvinylidenedifluoride (PVDC) staining with Coomassie brilliant blue G-250 
(below). Finally, the enzyme's catalytic activity was assayed in liver microsomes 
(Panel C). The results are expressed as the means ± SEM, n = 4. (*) p < 0.05, (**) p 
< 0.01 vs. control group, (#) p < 0.05 vs. the group treated with 25 mmol G/kg of 
diet. 
 
Fig. 7. Expression of LDL-receptor– and SREBF-2–mRNA transcription in mice fed 
geraniol. The mRNA was obtained from the livers of mice after three weeks of 
treatment as described in Materials and Methods and the relative amount (with 
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respect to ß-actin) of LDL receptor- (Panel A) and SREBF2- (Panel B) mRNA 
determined. The results are expressed as the means ± SEM, with n = 4, (*) p < 0.05 
vs. the control group. 
 
Fig. 8. The effect of geraniol on ACACA- and VLDL-receptor–mRNA transcription. 
mRNA was obtained from the mouse livers and the relative amount (with respect to 
ß-actin) of ACACA- (Panel A) and VLDL receptor- (Panel B) mRNA determined. 
The results are expressed as the means ± SEM, with n = 4, (*) p < 0.05 vs. the 
control group. 
 
Fig. 9. Proposed model for the effects of geraniol. The geraniol mechanisms of 
action proposed are represented in this panel. The Kyoto Encyclopedia of Genes and 
Genomes (Kegg) symbols were used representing gene expression (O), gene 
repression (IO), transcriptional or post-transcriptional gene repression (-----|) 
protein activation () and protein inhibition (–|). The genes up-regulated in the in 
silico analysis are in red and those down-regulated in green.Genes are named with 
the official symbol according to HGNC (HUGO Gene Nomenclature Committee). 
TG: Triglycerides; FA: fatty acids.  
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